Web Tool to Help Postmenopausal Women Decide on Fracture Prevention Medicine
Tests a web decision aid helping postmenopausal women choose whether to start bone-protecting treatment.
Plain-language title generated from the registry record
Registry title: Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for postmenopausal women over 50 with no earlier fragility fracture who are considered candidates for medicine to prevent fractures. It tests a web-based decision aid.
- Age
- Older than 50 years
- Sex
- Women only (postmenopausal)
- Disease stage
- 10-year risk of a major fracture above 5% by the FRAX assessment; a bone density (BMD) measurement is optional.
- Earlier treatment
- Must not be treated with bisphosphonates or other osteoporosis drugs (vitamin D and calcium supplements are allowed).
Main reasons for not taking part
- A history of fragility fracture
- Treatment with bisphosphonates or other osteoporosis drugs
- Serious other illnesses such as cancer or chronic kidney failure
- Permanent treatment with glucocorticoids
Read by machine on 12 November 2026.
Where in Spain
- Institut de Recerca Hospital de la Santa Creu i Sant PauBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07120854
- Record updated
- 13 August 2025
- Original description
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be difficult due to potential risks and side effects.Read full original descriptionShow less
Evaluation of a Decision Analysis Model in a Decision Aid for Fracture Prevention in Postmenopausal Women: Randomized Clinical Trial.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be difficult due to potential risks and side effects.
This study will test a web-based tool designed to help women make informed decisions about fracture prevention treatment. The tool provides information about the benefits and risks of treatment. Some women in the study will also receive additional support through a decision analysis report, which helps weigh different factors when making a choice.
The study will examine whether using this tool improves decision-making, increases confidence in making a choice, and enhances satisfaction with the decision. It will also explore what factors influence women's decisions and at what level of risk they choose to start treatment.
By understanding how decision aids impact choices, researchers aim to improve the way healthcare providers support patients in making informed decisions about their health.
Inclusion: Postmenopausal women older than 50 years; No medical history of fragility fractures; With or without a BMD measurement performed; Having been considered candidates to pharmacological treatment prevention for fragility fractures; A 10 year fracture risk assessment according to FRAX for Major fracture >5%.
Exclusion: suffer from serious concomitant pathologies (cancer, chronic renal insufficiency, etc.); women under permanent treatment with glucocorticoids; women with a history of fragility fracture; being treated with bisphosphonates or other osteoporosis drugs (except for vitamin D and calcium supplements.